12/5/2008

Research shows a higher dose of the chemotherapy drug daunorubicin increased median survival rates for patients with previously untreated acute myeloid leukemia, when compared with using the standard dosage. Patients in the high-dose group had overall survival of 23.7 months, compared to 15.1 months for patients in the standard-dose group.

Full Story:
Yahoo!

Related Summaries